|
| 產地 | 進口、國產 |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS12160 |
| 應用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-SNF5 |
| 克隆性 | 是 |
| 靶點 | 詳見說明書 |
| 適應物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human SNF5 |
產品訂購信息：
英文名稱 Anti-SNF5
中文名稱 轉錄調控激活蛋白SNF5抗體說明書
別 名 Snr1; TYE4; BAF47; hSNF5; INI1 antibody Integrase interactor 1 protein; RDT; Sfh1p; SMARCB1; SNF5; SNF5L1; Snr1; Sucrose nonfermenting yeast homolog like 1; SWI/SNF complex component SNF5; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1; SWI10; Transcription factor TYE4; Transcription regulatory protein SNF5.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應 Human, Mouse, Rat, Chicken, Cow, Horse, Rabbit
產品類型 一抗
研究領域 染色質和核信號 信號轉導
蛋白分子量 predicted molecular weight: 44kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SNF5
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
轉錄調控激活蛋白SNF5抗體說明書 產品應用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產品介紹 SNF5 is involved in transcriptional activation. The SWI/SNF complex is required for the induced expression of a large number of genes. This complex alters chromatin structure to facilitate binding of gene-specific dedicated transcription factors. SNF5 also funtions as a tumor suppressor gene and is frequently mutated in malignant rhabdoid tumors. It is also involved in adipocyte differentiation.
Function : Core component of the BAF (hSWI/SNF) complex. This ATP-dependent chromatin-remodeling complex plays important roles in cell proliferation and differentiation, in cellular antiviral activities and inhibition of tumor formation. The BAF complex is able to create a stable, altered form of chromatin that constrains fewer negative supercoils than normal. This change in supercoiling would be due to the conversion of up to one-half of the nucleosomes on polynucleosomal arrays into asymmetric structures, termed altosomes, each composed of 2 histones octamers. Stimulates in vitro the remodeling activity of SMARCA4/BRG1/BAF190A. Involved in activation of CSF1 promoter. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a post-mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity). Plays a key role in cell-cycle control and causes cell cycle arrest in G0/G1. Also involved in vitamin D-coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR-mediated transrepression of the CYP27B1 gene.
Subunit : Component of the BAF (hSWI/SNF) complex, which includes at least actin (ACTB), ARID1A, ARID1B/BAF250, SMARCA2, SMARCA4/BRG1/BAF190A, ACTL6A/BAF53, ACTL6B/BAF53B, SMARCE1/BAF57 SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, and one or more of SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C. In muscle cells, the BAF complex also contains DPF3. Component of the WINAC complex, at least composed of SMARCA2, SMARCA4, SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCE1, ACTL6A, BAZ1B/WSTF, ARID1A, SUPT16H, CHAF1A and TOP2B. Binds to double-stranded DNA. Interacts with MYK and MAEL. Interacts with PPP1R15A. Binds tightly to the human immunodeficiency virus-type 1 (HIV-1) integrase in vitro and stimulates its DNA-joining activity. Interacts with human papillomavirus 18 E1 protein to stimulate its viral replication. Interacts with Epstein-Barr virus protein EBNA-2. Component of neural progenitors-specific chromatin remodeling complex (npBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, PHF10/BAF45A, ACTL6A/BAF53A and actin. Component of neuron-specific chromatin remodeling complex (nBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B, DPF3/BAF45C, ACTL6B/BAF53B and actin (By similarity).
Subcellular Location : Nucleus.
Post-translational modifications : Phosphorylated upon DNA damage, probably by ATM or ATR.
DISEASE : Defects in SMARCB1 are a cause of schwannomatosis (SCHWA) [MIM:162091]; also called congenital cutaneous neurilemmomatosis. Schwannomas are benign tumors of the peripheral nerve sheath that usually occur singly in otherwise normal individuals. Multiple schwannomas in the same individual suggest an underlying tumor-predisposition syndrome. The most common such syndrome is NF2. The hallmark of NF2 is the development of bilateral vestibular-nerve schwannomas; but two-thirds or more of all NF2-affected individuals develop schwannomas in other locations, and dermal schwannomas may precede vestibular tumors in NF2-affected children. There have been several reports of individuals with multiple schwannomas who do not show evidence of vestibular schwannoma. Clinical report suggests that schwannomatosis is a clinical entity distinct from other forms of neurofibromatosis.
Similarity : Belongs to the SNF5 family.
轉運蛋白SEC61B 多克隆抗體 SC61B Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
內質網蛋白SC65 多克隆抗體 SC65 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
溶質載體家族6成員3 多克隆抗體 SC6A3 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
溶質載體家族6成員4 多克隆抗體 SC6A4 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
溶質載體家族6成員7 多克隆抗體 SC6A7 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
磷酸化ADP核糖基化因子結合蛋白2抗體 轉錄因子NAC1抗體
錨蛋白重復及SAM結構域蛋白3抗體 轉錄因子MYB相關蛋白B抗體
磷酸化有絲分裂激酶B/C抗體 轉錄因子LMCD1抗體
磷酸化腺泡Acinus蛋白抗體 轉錄因子LHX6抗體
APS抗體 轉錄因子LBX1抗體
轉鐵蛋白 單克隆抗體 Transferrin Monoclonal Antibody 700/30ul#1540/100ul#2520/200ul
轉鐵蛋白 單克隆抗體 Transferrin Monoclonal Antibody 700/30ul#1540/100ul#2520/200ul
轉鐵蛋白 單克隆抗體 Transferrin Monoclonal Antibody 700/30ul#1540/100ul#2520/200ul
轉鐵蛋白 單克隆抗體 Transferrin Monoclonal Antibody 700/30ul#1540/100ul#2520/200ul
單克隆抗體 Digoxin Monoclonal Antibody 700/30ul#1540/100ul#2520/200ul
冬凌草 Rabdosia rubescens(Hemsl.)Hara Ponicidin 冬凌草乙素 52617-37-5 C20H26O6 ≥98%
異啊魏醋IsofqrulicccidHPLC≥97%，20mg/支
柯伊利素-7-O-葡萄糖苷 Chrysoeriol 7-O-glucoside 19993-32-9 20mg HPLC≥98% 柯伊利素-7-O-葡萄糖苷 19993-...
中藥對照藥材寬筋藤121391-200401TLC法鑒別
Escin IIA;Aescin IIA七葉皂苷C純度
轉錄調控激活蛋白SNF5抗體說明書豆科植物甘草 Glycyrrhiza uralensis Fisch. Neoisoliquiritin 新異甘草苷 7014-39-3 C21H22O9 ≥98%
澤瀉醇BclisolB18649-93-910mg
黃芩Scellaria baicalesis 2',5,6',7-Teaxy7noxyflavanone none 80604-16-6 C15H12O6 單元素西溶液成分分析標準物質080594
中藥對照藥材番石榴葉121212-0101TLC法鑒別
Dephnoretin西瑞香素 純度：≥98%
抗體的生物素化標記實驗要點：
1. 轉錄調控激活蛋白SNF5抗體說明書 如在反應混合液中有疊氮鈉或游離氨基存在,會抑制標記反應。因此,蛋白質在反應前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質之間的分子比按蛋白質表面的ε-氨基的密度會有所不同,選擇不當則影響標記的效率,應先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結合位點可能因此被封閉,導致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結合力或活性；
6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結合；
7.交聯反應后,應充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結合產生競爭作用；
8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導致高本底。
抗體的鑒定：
1）轉錄調控激活蛋白SNF5抗體說明書 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應,瓊脂擴散試驗,酶聯免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應抗原或近似抗原物質的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應率來表示。交叉反應率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結合率,求出各自在IC50時的濃度,并按公式計算交叉反應率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質的交叉反應率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結合位點與抗原決定簇之間立體構型的合適度決定的。有助于維持抗原抗體復合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。
